EGFR is mutated in 3.12% of malignant brain neoplasm patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

Afatinib is the most frequent therapy in malignant brain neoplasm trials with EGFR mutations as inclusion criteria [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is mutated in 4.17% of malignant brain neoplasm patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].